The federal government is ending a temporary subsidy that has quietly held down Medicare prescription-drug premiums for two years, and the Centers for Medicare and Medicaid Services now projects that roughly half of stand-alone Part D plans could charge more in 2027. The Part D Premium Stabilization Demonstration expires at the end of 2026, returning the program to ordinary market pricing. For millions of older Americans on fixed incomes, the shift arrives just as fall enrollment opens, yet the exact new cost will not be visible for weeks.
Why the Part D premium subsidy is disappearing after 2026
The demonstration was created in 2024 to cushion stand-alone prescription-drug plans while the Inflation Reduction Act reshaped the Part D benefit. It cut the base beneficiary premium, capped how much a plan’s premium could rise year over year, and narrowed the financial risk insurers carried. Those props kept sticker prices from jumping as the redesigned benefit, including a new annual out-of-pocket cap, took hold. Federal officials originally suggested the demonstration could run for at least three years.
Stand-alone Part D plans are the coverage of choice for older Americans who stay in original Medicare and buy separate drug protection, and that group leans heavily toward people managing chronic conditions and steady prescription costs. Because they do not have a Medicare Advantage plan folding drug coverage into a single premium, the stabilization subsidy was doing much of the work of keeping their monthly charge flat. Removing it puts the entire adjustment onto that stand-alone premium.
That timeline has been cut short. The agency says its review of the bids insurers submitted for 2027 shows plan sponsors now have enough experience under the redesigned benefit to price coverage without the extra support, so it will let the program lapse to return Part D to traditional market conditions. It laid out that reasoning when it released the national average bid figures for 2027.
Free retirement updates: Miss an enrollment or claim deadline and it may be gone. Our free Retirement Shield newsletter keeps readers ahead of the ones that matter. Get the free newsletter.
What could happen to stand-alone drug-plan premiums in 2027
Independent analysts warn that the people most exposed are those who buy stand-alone Part D plans and pair them with traditional Medicare, rather than getting drug coverage bundled inside a Medicare Advantage plan. One review found that without the stabilization program, premiums for beneficiaries who had stayed in their 2024 plan would have nearly doubled on average, a jump the subsidy absorbed. An analysis by health-policy researchers at KFF concluded some beneficiaries could face larger premium increases next year.
Some perspective on scale helps explain the concern. The base beneficiary premium is only one slice of a Part D bill, but it is the slice the demonstration held down most directly, trimming it by a set amount and capping year-over-year jumps. With those guardrails gone, a plan that had been artificially restrained can reset toward what its underlying costs actually justify, and the plans that leaned hardest on the subsidy are the ones with the most room to climb. That is why the same policy change can barely move one plan’s premium while pushing another’s up sharply.
The change touches monthly premiums, not the drug prices themselves. The Inflation Reduction Act’s $2,000 annual cap on out-of-pocket drug spending remains in place for 2026 and beyond, and the government’s move does not undo it. What is ending is the mechanism that softened the premium — the recurring monthly charge a person pays simply to hold the plan — so the risk is concentrated in that line of the bill.
The agency has framed the expected increases as modest, describing the demonstration’s original figures in its 2027 Parts C and D rate announcement. Outside forecasters are less reassured, noting that stand-alone plans have thinner margins and fewer ways to spread costs than the larger Advantage insurers, which could leave certain plans raising premiums more sharply than the averages suggest.
Why the real 2027 price stays hidden until late September
The frustrating part for anyone trying to plan is timing. The agency does not publish final 2027 plan premiums, formularies, and pharmacy networks until late September, which means the people weighing whether to keep or drop a plan cannot yet see what their own coverage will cost. The announcement that the subsidy is ending has arrived well ahead of the numbers that would let a household judge the actual damage.
Those prices matter because the calendar does not wait. Medicare’s fall open enrollment runs October 15 to December 7, the main annual window to switch drug plans or move between traditional Medicare and Medicare Advantage. A plan chosen during that window locks in for all of 2027, so the decision has to be made in a narrow stretch right after the real premiums finally appear.
The comparison itself runs through Medicare’s Plan Finder, the official tool that lists each plan’s premium, deductible, covered drugs, and preferred pharmacies once the 2027 data loads. Until that information posts, the tool shows only the expiring 2026 figures, so a beneficiary checking early sees last year’s prices rather than the ones that will apply. The practical effect is that meaningful shopping cannot begin until the final numbers arrive, compressing the real decision window even though the enrollment period on paper spans roughly eight weeks.
That leaves a compressed sequence: confirmation the cushion is gone now, the true premiums in late September, and roughly seven weeks to act. The open question is how many beneficiaries will notice the subsidy’s quiet end in time to compare plans before the enrollment window closes, and how many will discover the higher premium only when the first 2027 payment comes due.
This article was produced with AI assistance and reviewed against primary sources by The Money Overview editorial team.
More Financial Reading
